2020
DOI: 10.1016/j.metabol.2020.154246
|View full text |Cite
|
Sign up to set email alerts
|

11β-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
23
0
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(25 citation statements)
references
References 94 publications
0
23
0
2
Order By: Relevance
“…Similarly, declining cognitive function with ageing in mice is also characterized by dysregulation of glucocorticoids in the hippocampus (31). Excessive glucocorticoid activity within tissues, independently of circulating glucocorticoids, has been proposed as a common underlying cause of metabolic and ageing-related diseases and has led to the development of HSD11B1 inhibitors for these conditions (32).…”
Section: The Glucocorticoid System and Its Dysregulation In Metabolic Diseasementioning
confidence: 99%
“…Similarly, declining cognitive function with ageing in mice is also characterized by dysregulation of glucocorticoids in the hippocampus (31). Excessive glucocorticoid activity within tissues, independently of circulating glucocorticoids, has been proposed as a common underlying cause of metabolic and ageing-related diseases and has led to the development of HSD11B1 inhibitors for these conditions (32).…”
Section: The Glucocorticoid System and Its Dysregulation In Metabolic Diseasementioning
confidence: 99%
“…More recently, the role of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD1) has been considered [ 32 ]. This enzyme is one of the most promising molecular targets to treat Type 2 diabetes mellitus and its complications [ 33 ]. Basically, 11β-HSD1 is able to catalyze the production of cortisol, and the levels of 11β-HSD1 correspond to the levels of cortisol concentration [ 29 ].…”
Section: Cortisol and Sudden Deathmentioning
confidence: 99%
“…Moreover, enhanced activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) has been detected in the fat tissue of obese patients, inducing local cortisol excess (tissue-Cushing) [ 41 , 42 , 43 ]. Therefore, a selective inhibitor of 11βHSD1 has been suggested as a plausible drug, reducing local cortisol concentrations in various organs, also within the adipose tissue [ 44 , 45 ].At the same time, adipose tissue itself remains an active endocrine organ, and the concentration of its hormones, such as leptin and adiponectin, can directly or indirectly affect steroid metabolism. In mice, leptin modulates the functioning of the HPA axis through its hypothalamic receptor and limits stress-responsive CRH secretion [ 25 , 46 ].…”
Section: Discussionmentioning
confidence: 99%